Aaron M. Moss

595 total citations
10 papers, 453 citations indexed

About

Aaron M. Moss is a scholar working on Oncology, Infectious Diseases and Physiology. According to data from OpenAlex, Aaron M. Moss has authored 10 papers receiving a total of 453 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Infectious Diseases and 3 papers in Physiology. Recurrent topics in Aaron M. Moss's work include HIV/AIDS drug development and treatment (4 papers), Adenosine and Purinergic Signaling (3 papers) and Drug Transport and Resistance Mechanisms (2 papers). Aaron M. Moss is often cited by papers focused on HIV/AIDS drug development and treatment (4 papers), Adenosine and Purinergic Signaling (3 papers) and Drug Transport and Resistance Mechanisms (2 papers). Aaron M. Moss collaborates with scholars based in United States, Sweden and Japan. Aaron M. Moss's co-authors include Ana Ruiz-Garcı́a, V.G. Casabó, Marival Bermejo, Christopher J. Endres, Jashvant D. Unadkat, Rajgopal Govindarajan, Gus R. Rosania, Pär Matsson, Xiaoyan Chu and Swati Nagar and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Aaron M. Moss

10 papers receiving 444 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aaron M. Moss United States	7	193	117	114	85	61	10	453
Faraz Kazmi United States	10	156 0.8×	246 2.1×	194 1.7×	56 0.7×	41 0.7×	17	591
Christine M. Bowman United States	15	277 1.4×	197 1.7×	298 2.6×	76 0.9×	40 0.7×	30	668
Paresh P. Chothe United States	14	299 1.5×	129 1.1×	178 1.6×	139 1.6×	27 0.4×	34	571
Tomáš Smutný Czechia	17	162 0.8×	219 1.9×	224 2.0×	50 0.6×	49 0.8×	33	710
Tom De Bruyn Belgium	12	386 2.0×	217 1.9×	117 1.0×	163 1.9×	62 1.0×	35	647
Kunihiro Yoshisue Japan	13	337 1.7×	242 2.1×	192 1.7×	76 0.9×	27 0.4×	32	607
Gunilla Englund Sweden	6	436 2.3×	124 1.1×	109 1.0×	207 2.4×	66 1.1×	6	608
Émilie Jigorel France	6	410 2.1×	250 2.1×	115 1.0×	165 1.9×	46 0.8×	6	593
B. Kevin Park United Kingdom	13	93 0.5×	157 1.3×	151 1.3×	64 0.8×	61 1.0×	15	485
Bill J. Smith United States	15	143 0.7×	159 1.4×	243 2.1×	31 0.4×	46 0.8×	25	636

Countries citing papers authored by Aaron M. Moss

Since Specialization

Citations

This map shows the geographic impact of Aaron M. Moss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aaron M. Moss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aaron M. Moss more than expected).

Fields of papers citing papers by Aaron M. Moss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aaron M. Moss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aaron M. Moss. The network helps show where Aaron M. Moss may publish in the future.

Co-authorship network of co-authors of Aaron M. Moss

This figure shows the co-authorship network connecting the top 25 collaborators of Aaron M. Moss. A scholar is included among the top collaborators of Aaron M. Moss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aaron M. Moss. Aaron M. Moss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Kim, Richard D., James M. Cleary, Alexis D. Leal, et al.. (2021). A phase 1 study of TAK-164, an anti-guanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) cancers expressing GCC.. Journal of Clinical Oncology. 39(15_suppl). 3050–3050. 3 indexed citations

Dodds, Michael, et al.. (2019). Target‐Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model‐Informed Dose Selection for the First‐in‐Human Study of AVB‐S6‐500. Clinical and Translational Science. 13(1). 204–211. 18 indexed citations

Dillon, Stacey R., Katherine E. Lewis, Ryan Swanson, et al.. (2018). A Dual ICOS/CD28 Antagonist ICOSL Variant Ig Domain (vIgD) Potently Suppresses Human Mixed Lymphocyte Reactions and Human/NSG Mouse Xenograft Graft vs. Host Disease (GvHD). Biology of Blood and Marrow Transplantation. 24(3). S187–S188. 2 indexed citations

Endres, Christopher J., Aaron M. Moss, Kazuya Ishida, Rajgopal Govindarajan, & Jashvant D. Unadkat. (2016). The role of the equilibrative nucleoside transporter 1 on tissue and fetal distribution of ribavirin in the mouse. Biopharmaceutics & Drug Disposition. 37(6). 336–344. 10 indexed citations

Moss, Aaron M., Jean Gudas, Tina Albertson, Nancy Whiting, & Che‐Leung Law. (2014). Abstract 104: Preclinical microPET/CT imaging of 89Zr-Df-SGN-35 in mice bearing xenografted CD30 expressing and non-expressing tumors. Cancer Research. 74(19_Supplement). 104–104. 5 indexed citations

Chu, Xiaoyan, Ken Korzekwa, Robert Elsby, et al.. (2013). Intracellular Drug Concentrations and Transporters: Measurement, Modeling, and Implications for the Liver. Clinical Pharmacology & Therapeutics. 94(1). 126–141. 193 indexed citations

Moss, Aaron M., Christopher J. Endres, Ana Ruiz-Garcı́a, Doo‐Sup Choi, & Jashvant D. Unadkat. (2012). Role of the Equilibrative and Concentrative Nucleoside Transporters in the Intestinal Absorption of the Nucleoside Drug, Ribavirin, in Wild-Type and Ent1(−/−) Mice. Molecular Pharmaceutics. 9(9). 2442–2449. 17 indexed citations

Endres, Christopher J., et al.. (2009). The Role of Nucleoside Transporters in the Erythrocyte Disposition and Oral Absorption of Ribavirin in the Wild-Type and Equilibrative Nucleoside Transporter 1(−/−) Mice. Journal of Pharmacology and Experimental Therapeutics. 331(1). 287–296. 24 indexed citations

Endres, Christopher J., Aaron M. Moss, Rajgopal Govindarajan, et al.. (2009). The Role of the Equilibrative Nucleoside Transporter 1 (ENT1) in Transport and Metabolism of Ribavirin by Human and Wild-Type or Ent1(-/-) Mouse Erythrocytes. Journal of Pharmacology and Experimental Therapeutics. 329(1). 387–398. 54 indexed citations

10.

Ruiz-Garcı́a, Ana, Marival Bermejo, Aaron M. Moss, & V.G. Casabó. (2007). Pharmacokinetics in Drug Discovery. Journal of Pharmaceutical Sciences. 97(2). 654–690. 127 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact